---
document_datetime: 2023-09-21 17:05:20
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mabcampath-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: mabcampath-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.46255
conversion_datetime: 2025-12-25 01:46:32.027609
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

| No      | Scope                                                                                            | Opinion/                            | Commission                            | Product                   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0055  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | Notification 1 issued on 12/06/2012 | Decision Issued 2 / amended on n/a no | Information affected 3 PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| R/0054  | Renewal of the marketing authorisation.                                                          | 17/03/2011 product                  | 12/05/2011                            | SPC, Annex II, PL         | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of MabCampath continues to be favourable. The CHMP is also of the opinion that the renewal can be granted with unlimited validity. The PSUR cycle for this product should be maintained as a once-yearly submission as currently a number of adverse events are under close surveillance. |
| II/0053 | The change relates to the replacement of                                                         | 22/04/2010                          | 05/05/2010                            |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

7 Westferry Circus

●

Canary Wharf

●

London E14 4HB

●

United Kingdom

<!-- image -->

<!-- image -->

Telephone +44 (0)20 7418 8400 Facsimile +44 (0) 20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union MabCampath Procedural steps taken and scientific information after the authorisation Changes made after 1 December 2004 For procedures finalised before 1 December 2004, please refer to 'Procedural steps taken until cut-off date' 1 Notifications are issued for type I variations (unless part of a group or a worksharing application). Opinions are issued for all other procedures. 2 No Commission Decision is issued for type IA and type IB variations or for type II variations and annual re-assessments that do not affect the annexes. 3 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0052 | raw material and suppliers used in the cell culture process in the manufacturing process of the active substance. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological active substance or a starting material […] used in the manufacture of a biological/immunological product Increase to the current fill volume of MabCampath. The currently approved fill | 21/01/2010                          | 04/02/2010                                  |                                  | longer    |
| N/0050  | volume of 1.1 ml will be increased to 1.15ml. Change(s) to the manufacturing process for the finished product Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                     | 30/11/2009                          | n/a no                                      | PL                               |           |
| II/0049 | Addition of a manufacturing site for the finished product Quality changes product                                                                                                                                                                                                                                                                                                                                                                  | 22/10/2009                          | 26/11/2009                                  |                                  |           |
| II/0047 | Changes to the manufacturing process for the active substance. Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                     | 19/11/2009                          | 26/11/2009                                  |                                  |           |
| II/0048 | Addition of a manufacturer of the active substance Quality changes                                                                                                                                                                                                                                                                                                                                                                                 | 22/10/2009                          | 20/11/2009                                  | Annex II                         |           |

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0051 | 16_b_Submission of new TSE certificate relating to active substance - other substances                                                                                                                                                                                                                                                                                                              | 20/11/2009                          | n/a                                         |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| N/0043  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                    | 17/07/2009                          | n/a                                         | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0046 | 25_b_01_Change to comply with Ph. - compliance with EU Ph. update - active substance                                                                                                                                                                                                                                                                                                                | 13/07/2009                          | n/a                                         |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0045 | 07_a_Replacement/add. of manufacturing site: Secondary packaging site, 08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                                                                                                                                                                | 25/06/2009                          | n/a                                         | Annex II, PL longer              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0044 | 07_a_Replacement/add. of manufacturing site: Secondary packaging site, 08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                                                                                                                                                                | 25/06/2009                          | n/a no                                      | Annex II, PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| N/0042  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                    | 11/05/2009                          | n/a                                         | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0040 | Update of SPC section 4.4 regarding the wording on transfusion associated graft versus host disease (TAGVHD). In addition, SPC sections 4.2, 4.3, 4.4, 4.8 and 4.9 are proposed to be updated and corrected based on the latest version of the CCDS. Section 2 of the PL is proposed to be amended accordingly. Update of Summary of Product Characteristics, Labelling and Package Leaflet product | 23/10/2008                          | 05/12/2008                                  | SPC, Annex II, PL                | A fatal case of Transfusion Associated Graft Versus Host Disease (TAGVHD) was reported in an investigator sponsored study CALGB 10101. TAGVHD is a rare and generally fatal immunological complication of transfusion practice, involving the engraftment and clonal expansion of viable donor lymphocytes contained in transfused blood components in a susceptible host. Although the induction and consolidation treatment regimen received by this patient may have facilitated the development of TAGVHD, no individual agent can be identified as the sole or pre- eminent cause, since each drug has complex immunosuppressive properties, potentially increasing the susceptibility to developing TAGVHD. B-CLL patients may also be at increased risk of TAGVHD. Therefore, SPC section 4.4 has been updated to recommend that patients who have been treated with alemtuzumab receive irradiated blood products. In addition, various updates and corrections to SPC sections 4.2, |

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0037 | Change in test procedures for active substance and finished product. Change(s) to the test method(s) and/or specifications for the active substance | 24/07/2008                          | 29/07/2008                                  |                                  | longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| S/0035  | 6th annual re-assessment Annual reassessment                                                                                                        | 24/04/2008                          | 04/07/2008 no                               | SPC, Annex II, Labelling, PL     | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing Authorisation Holder and having reassessed the benefit/risk profile of MabCampath concluded that the benefit/risk remains favourable and since all specific obligations have been fulfilled, there are no remaining grounds for the Marketing Authorisations to remain under exceptional circumstances. The SPC, Annex II, labelling and the Package Leaflet have been updated in line with the conclusions of the CHMP to reflect the fact that the Marketing Authorisation is no longer under exceptional circumstances. |
| IB/0039 | 15_b_01_Submission of Ph. Eur. certificate for active substance - new manuf./sterile substance product                                              | 04/07/2008                          | n/a                                         |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0038 | 15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                | 06/06/2008                          | n/a                                         |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| N/0036  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                    | 05/03/2008                          | n/a                                         | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                          |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0034  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                    | 14/02/2008                          | n/a                                         | PL                               |                                                                                                                                                                                                                                                                                                                                                                  |
| II/0030 | Extension of the indication in the treatment of B-cell chronic lymphocytic leukaemia (B- CLL) in patients for whom fludarabine combination chemotherapy is not appropriate. Extension of Indication | 18/10/2007                          | 19/12/2007                                  | SPC, Annex II, PL                | Please refer to Scientific Discussion: MabCampath-H-353-II-30. longer                                                                                                                                                                                                                                                                                            |
| II/0028 | Change(s) to the manufacturing process for the finished product                                                                                                                                     | 19/07/2007                          | 23/07/2007                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0033 | 05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                      | 20/04/2007                          | n/a                                         | Annex II, PL                     |                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0032 | 38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                     | 08/05/2007                          | n/a no                                      | IB/0032                          |                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0031 | 38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                     | 08/05/2007                          | n/a 22/03/2007                              |                                  | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile of the medicinal product, recommended that no amendment of the Annexes of the Commission Decision is necessary and that the marketing authorisation remains under exceptional |
| S/0027  | 5th Annual Reassessment Annual reassessment                                                                                                                                                         | 22/03/2007                          | product                                     |                                  | circumstances.                                                                                                                                                                                                                                                                                                                                                   |
| II/0026 | Change(s) to the manufacturing process the active substance                                                                                                                                         | 22/02/2007                          | for 28/02/2007                              |                                  |                                                                                                                                                                                                                                                                                                                                                                  |
| R/0022  | Renewal of the marketing authorisation                                                                                                                                                              | 01/06/2006                          | 28/07/2006                                  | SPC, Annex II, Labelling, PL     |                                                                                                                                                                                                                                                                                                                                                                  |
| II/0021 | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                      | 23/03/2006                          | 29/03/2006                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                  |
| N/0020  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3                                                                                                                  | 08/11/2005                          | n/a                                         | PL                               |                                                                                                                                                                                                                                                                                                                                                                  |

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                   | Opinion/ Notification   | Commission                     | Product Summary                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|-------------------------------------------------------------------------|-------------------------|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         | Notification)                                                           | issued on               | Decision Issued 2 / amended on | Information affected 3                                                                                                                                                                                                                                                                                                                                                                                                                           |
| S/0019  | Annual reassessment                                                     | 13/10/2005              | 13/10/2005                     | On the basis of the submitted data, the CHMP, having reviewed the compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, is of the opinion that the quality, safety and efficacy continues to be to be favourable for MabCampath in the approved indication. It is recommended that the marketing authorisation remains under exceptional circumstances. longer |
| T/0018  | Transfer of Marketing Authorisation Holder                              | 15/07/2005              | 16/08/2005                     | SPC, Labelling, PL The Marketing Authorisation Holder was transferred from ILEX Pharmaceuticals Ltd to Genzyme Europe BV.                                                                                                                                                                                                                                                                                                                        |
| II/0017 | Change(s) to container                                                  | 21/04/2005              | 27/04/2005                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0016 | 42_a_01_Change in shelf-life of finished product - as packaged for sale | 16/02/2005              | n/a                            | SPC                                                                                                                                                                                                                                                                                                                                                                                                                                              |

product - as packaged for sale Medicinal product no longer authorised